Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2010

Evers Bastiaan, Schut Eva, van der Burg Eline, Braumuller Tanya M, Egan David A, Holstege Henne, Edser Pauline, Adams David J, Wade-Martins Richard, Bouwman Peter, Jonkers Jos

Abstract excerpt

PURPOSE: Hereditary breast cancer is partly explained by germline mutations in BRCA1 and BRCA2. Although patients carry heterozygous mutations, their tumors have typically lost the remaining wild-type allele. Selectively targeting BRCA deficiency may therefore constitute an important therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Delivery Systems

Share to Drug Synergism

Share to Mammary Neoplasms, Animal

Share to Phthalazines

Share to Piperazines

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 20008842
DOI: 10.1158/1078-0432.CCR-09-2434
PMCID: PMC2802735

Genes

BRCA2
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20008842-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.PMID 20008842Read ↗

Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.Semantic proximity Read ↗

The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethalitySemantic proximity Read ↗

Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.Semantic proximity Read ↗

Targeted therapies for breast cancer.Semantic proximity Read ↗

Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approachesSemantic proximity Read ↗

From Small Molecules to Degraders and AI: Contemporary Trends and Future Directions in Anticancer Drug DiscoverySemantic proximity Read ↗

From Small Molecules to Degraders and AI: Contemporary Trends and Future Directions in Anticancer Drug DiscoverySemantic proximity Read ↗

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparibSemantic proximity Read ↗

Natural Small Molecules in Breast Cancer Treatment: Understandings from a Therapeutic ViewpointSemantic proximity Read ↗

Development of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cells.Semantic proximity Read ↗

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair.Semantic proximity Read ↗

Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.